Pharmacokinetics test of pyridoxamine in uremic patients on peritoneal dialysis
- Conditions
- End-stage renal disease
- Registration Number
- JPRN-UMIN000007169
- Lead Sponsor
- Tokai University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Not provided
Receiving hemodialysis in addition to peritoneal dialysis Severe liver disease or liver dysfunction History of allergy or adverse effects to certain drugs Participating in other clinical trials or received investigational products in the last 16 weeks Having active cancers or received complete resection of cancers in the last 3 years History of cardiovascular disease in the last 6 months Receiving peritoneal dialysis for more than 8 years or having suspected encapsulating peritoneal sclerosis Fontaine stage II peripheral arterial disease Treatment resistant hypertension Treatment resistant diabetes Erythropoietin resistant anemia Received aminophylline, theophylline, choline theophylline, or levodopa in the last 4 weeks Pregnant women or those intending to become pregnant during the next 1 year
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method